Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

Revista Española De Cardiología
David VivasExpert reviewers

Abstract

The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.

Citations

May 15, 2020·Clinical Chemistry and Laboratory Medicine : CCLM·Job Harenberg, Emmanuel Favaloro
Jun 8, 2021·Cardiovascular Drugs and Therapy·Pedro CastroMaribel Diaz-Ricart
Sep 22, 2021·Canadian Journal of Physiology and Pharmacology·Joey ChammasAdel Schwertani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

The Korean Journal of Internal Medicine
Kwan Yong LeeKorean Society of Interventional Cardiology COVID-19 Task Force Team
Archives of Pathology & Laboratory Medicine
Yang FeiWenjing Cao
© 2021 Meta ULC. All rights reserved